Seres’ SER-287 for UC Shows Positive Results in Phase 1b Trial

Seres’ SER-287 for UC Shows Positive Results in Phase 1b Trial
Seres Therapeutics announced positive topline results from the company’s Phase 1b placebo-controlled study investigating the effects of SER-287, a potential microbiome therapy, in patients with ulcerative colitis (UC) who failed to respond to current therapies. The study is ongoing and actively recruiting participants. The results revealed that patients treated with SER-287 showed a dose-dependent benefit in clinical remission rates, and an improvement of mucosal appearance by endoscopy. Importantly, the therapy did not raise safety concerns. "We are extremely pleased with these SER-287
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *